ACET - Adicet Bio, Inc. Stock Price, Fair Value and News

1.60USD+0.03 (+1.91%)Delayed

Market Summary

USD1.60+0.03

Delayed

1.91%

ACET Stock Price

View Fullscreen

ACET RSI Chart

ACET Valuation

Market Cap

131.5M

Price/Earnings (Trailing)

-0.94

Price/Sales (Trailing)

1.6

EV/EBITDA

0.87

Price/Free Cashflow

-1.38

ACET Price/Sales (Trailing)

ACET Profitability

EBT Margin

-204.53%

Return on Equity

-54.02%

Return on Assets

-47.7%

Free Cashflow Yield

-72.45%

ACET Fundamentals

ACET Revenue

Revenue (TTM)

68.3M

ACET Earnings

Earnings (TTM)

-139.8M

Earnings Growth (Yr)

9.28%

Earnings Growth (Qtr)

Breaking Down ACET Revenue

Last 7 days

8.8%

Last 30 days

-29.5%

Last 90 days

-45.6%

Trailing 12 Months

-75.2%

How does ACET drawdown profile look like?

ACET Financial Health

Current Ratio

14.34

ACET Investor Care

Shares Dilution (1Y)

91.29%

Diluted EPS (TTM)

-2.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	38.7M	33.9M	73.8M	68.3M
2021	0	20.7M	16.7M	19.1M
2020	5.2M	9.4M	13.7M	17.9M
2019	0	0	0	995.0K
2018	0	0	0	8.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Adicet Bio, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 25, 2024	gordon carl l	bought	7,500,000	2.4	3,125,000	-
Jan 25, 2024	orbimed advisors llc	bought	7,500,000	2.4	3,125,000	-
Jan 24, 2024	aftab blake	acquired	-	-	19,700	chief scientific officer
Jan 24, 2024	harvey brian nicholas	acquired	-	-	26,300	chief financial officer
Jan 24, 2024	aftab blake	sold (taxes)	-8,556	2.4	-3,565	chief scientific officer
Jan 24, 2024	galimi francesco	sold (taxes)	-11,896	2.4	-4,957	svp & chief medical officer
Jan 24, 2024	harvey brian nicholas	sold (taxes)	-10,368	2.4	-4,320	chief financial officer
Jan 24, 2024	schor chen	sold (taxes)	-36,696	2.4	-15,290	president & ceo
Jan 24, 2024	healey don	acquired	-	-	19,700	chief technology officer
Jan 24, 2024	galimi francesco	acquired	-	-	26,300	svp & chief medical officer

Which funds bought or sold ACET recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	7.34	3,163	12,617	-%
May 16, 2024	JANE STREET GROUP, LLC	added	154	94,194	137,686	-%
May 16, 2024	COMERICA BANK	new	-	5,497	5,497	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	13,899	9,359,050	9,413,130	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	113	149,462	239,697	-%
May 15, 2024	BARCLAYS PLC	reduced	-9.8	9,000	88,000	-%
May 15, 2024	MORGAN STANLEY	added	45.32	4,268,420	9,558,170	-%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	new	-	55,578	55,578	-%
May 15, 2024	Blackstone Inc.	new	-	2,905,660	2,905,660	0.01%
May 15, 2024	D. E. Shaw & Co., Inc.	reduced	-5.96	110,870	765,980	-%

Are Funds Buying or Selling ACET?

Are funds buying ACET calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ACET

No. of Funds

Unveiling Adicet Bio, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 21, 2024	orbimed advisors llc	11.9%	9,772,598	SC 13D/A
Feb 27, 2024	millennium management llc	5.2%	3,946,142	SC 13G
Feb 14, 2024	ecor1 capital, llc	0%	0	SC 13G/A
Feb 14, 2024	rtw investments, lp	9.6%	4,134,631	SC 13G/A
Feb 14, 2024	tang capital partners lp	7.8%	5,900,000	SC 13G/A
Feb 12, 2024	morgan stanley	6.4%	2,777,725	SC 13G
Feb 07, 2024	carlyle group inc.	4.1%	3,060,292	SC 13D/A
Feb 07, 2024	blackrock inc.	3.0%	2,111,898	SC 13G/A
Feb 05, 2024	ra capital management, l.p.	9.99%	7,696,949	SC 13G
Feb 02, 2024	cowen financial products llc	6.29%	2,715,278	SC 13G/A

Recent SEC filings of Adicet Bio, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	8-K	Current Report
May 10, 2024	8-K	Current Report
Apr 26, 2024	DEFR14A	DEFR14A
Apr 24, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 22, 2024	8-K	Current Report
Apr 12, 2024	PRE 14A	PRE 14A
Mar 22, 2024	8-K	Current Report

Peers (Alternatives to Adicet Bio, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Adicet Bio, Inc. News

Latest updates

Adicet Bio, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Revenue	100.0%	91,652,000	45,826,000	-	43,360,000	-	24,990,000	5,468,000	3,429,000	4,814,000	5,410,000	3,028,000	7,465,000	2,000,000	-	-
Operating Expenses	-2.2%	30,871,000	31,565,000	31,565,000	22,985,000	22,707,000	20,284,000	21,010,000	17,139,000	15,641,000	14,759,000	16,683,000	16,095,000	9,557,000	1,245,500	-10,200,000
S&GA Expenses	-100.0%	-	6,806,500	6,550,000	6,415,000	6,529,000	6,801,000	6,352,000	5,213,000	5,025,000	5,076,000	7,741,000	7,419,000	2,524,000	2,006,500	1,799,000
R&D Expenses	-3.5%	23,897,000	24,758,500	25,015,000	16,570,000	16,178,000	13,483,000	14,658,000	11,926,000	10,616,000	9,683,000	8,942,000	8,676,000	7,033,000	-761,000	-11,999,000
EBITDA Margin	2.4%	-1.95	-2.00	-0.98	-0.73	-1.36	-0.89	-3.16	-3.22	-2.64	-	-	-	-	-	-
Interest Expenses	300.0%	2,000	500	26,000	18,000	18,000	18,000	25,000	50,000	51,000	-	50,000	34,000	-	-	-
Income Taxes	-	-	-	-	-	-	-	-11,000	11,000	-77,000	-139,000	3,000	-	-2,679,000	3,000	-
Earnings Before Taxes	5.0%	-28,016,000	-29,489,000	-29,874,500	-21,996,000	-22,538,000	4,618,000	-15,824,000	-14,002,000	-10,931,000	-9,097,000	-14,776,000	-8,455,000	-7,165,000	4,740,500	21,969,000
EBT Margin	2.0%	-2.05	-2.09	-1.02	-0.76	-1.41	-0.93	-3.25	-3.32	-2.71	-	-	-	-	-	-
Net Income	5.0%	-28,016,000	-29,489,000	-29,874,500	-21,996,000	-22,538,000	4,618,000	-15,813,000	-14,013,000	-10,854,000	-8,958,000	-14,779,000	-8,455,000	-4,486,000	-28,890,000	-5,757,000
Net Income Margin	2.0%	-2.05	-2.09	-1.02	-0.75	-1.41	-0.93	-3.24	-3.31	-2.70	-	-	-	-	-	-
Free Cashflow	2.3%	-23,088,000	-23,622,000	-25,327,000	-20,139,000	-17,554,000	1,473,000	-16,522,000	-16,862,000	-14,910,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	41.4%	293	207	233	278	305	331	354	330	340	339	257	269	282	154	150	74.00	78.00	82.00	122	137	145
Current Assets	54.3%	250	162	186	209	235	261	286	264	282	282	199	216	229	100	117	74.00	78.00	64.00	121	136	145
Cash Equivalents	55.0%	248	160	183	205	232	258	283	261	278	278	192	209	222	89.00	85.00	18.00	7.00	15.00	23.00	21.00	7.00
Net PPE	-5.1%	25.00	27.00	28.00	30.00	30.00	29.00	27.00	23.00	18.00	15.00	11.00	11.00	3.00	3.00	2.00	0.00	0.00	2.00	0.00	0.00	0.00
Goodwill	-	-	-	-	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	20.00	20.00	21.00	-	-	-	-	-	-
Liabilities	-7.6%	34.00	37.00	39.00	39.00	39.00	38.00	37.00	37.00	29.00	36.00	40.00	40.00	46.00	44.00	33.00	4.00	3.00	28.00	12.00	10.00	5.00
Current Liabilities	-9.5%	17.00	19.00	20.00	19.00	18.00	20.00	17.00	16.00	10.00	16.00	20.00	21.00	25.00	22.00	30.00	4.00	3.00	15.00	12.00	10.00	5.00
Shareholder's Equity	52.1%	259	170	195	239	266	292	318	293	311	303	217	228	236	110	117	71.00	76.00	82.00	110	127	140
Retained Earnings	-7.4%	-408	-380	-351	-301	-268	-238	-208	-186	-163	-168	-152	-138	-127	-106	-97.37	-166	-161	-69.65	-125	-100	-82.46
Additional Paid-In Capital	21.2%	668	551	546	540	535	530	526	480	475	471	370	367	364	216	214	238	237	9.00	235	228	223
Shares Outstanding	89.9%	82.00	43.00	43.00	43.00	43.00	43.00	41.00	40.00	40.00	40.00	32.00	29.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	77.00	-	-	-	428	-	-	-	226	-	-	-	40.00	-	-	-	278	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	2.7%	-22,849	-23,486	-21,238	-24,899	-24,094	-18,837	-15,328	-14,705	4,105	-13,444	-9,684	-12,778	-15,146	-13,345	-7,849	-12,006	-8,352	-7,259	5,601	-14,175	-12,049
Share Based Compensation	15.6%	5,679	4,911	5,560	5,023	4,765	4,250	4,191	4,335	4,350	4,280	2,529	2,659	3,043	1,647	3,116	52.00	299	397	14.00	14.00	663
Cashflow From Investing	-75.7%	-239	-136	-906	-1,507	-1,915	-6,490	-4,811	-2,849	-2,632	-3,078	-7,178	-382	7,842	12,448	74,646	23,678	4,445	-5,014	-33,265	24,976	-34,628
Cashflow From Financing	145907.9%	110,966	76.00	-59.00	226	-7.00	304	42,176	163	-1,134	97,463	362	-27.00	144,887	267	144	-150	42.00	-123	26,702	3,550	46,816

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ACET Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 23,897	$ 26,756
General and administrative	6,974	6,566
Total operating expenses	30,871	33,322
Loss from operations	(30,871)	(33,322)
Interest income	2,918	2,666
Interest expense	(2)	(19)
Other expense, net	(61)	(206)
Loss before income tax provision	(28,016)	(30,881)
Income tax provision	0	0
Net loss	$ (28,016)	$ (30,881)
Net loss per share attributable to common stockholders, basic	$ (0.35)	$ (0.72)
Net loss per share attributable to common stockholders, diluted	$ (0.35)	$ (0.72)
Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, basic	79,071,652	42,955,688
Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, diluted	79,071,652	42,955,688

ACET Balance Sheet

2024-03-31

Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 247,589	$ 159,711
Prepaid expenses and other current assets	2,761	2,561
Total current assets	250,350	162,272
Property and equipment, net	25,407	26,777
Operating lease right-of-use asset	16,647	17,424
Other non-current assets	691	822
Total assets	293,095	207,295
Current liabilities:
Accounts payable	2,542	2,625
Accrued and other current liabilities	11,597	13,441
Operating lease liability	3,322	3,221
Total current liabilities	17,461	19,287
Operating lease liability, net of current portion	16,714	17,703
Other non-current liabilities	116	130
Total liabilities	34,291	37,120
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; none issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	0
Common stock, $0.0001 par value, 150,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 82,169,503 and 43,270,386 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	8	4
Additional paid-in capital	667,584	550,943
Accumulated deficit	(408,788)	(380,772)
Total stockholders’ equity	258,804	170,175
Total liabilities and stockholders’ equity	$ 293,095	$ 207,295

About Adicet Bio, Inc.

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.

CEO	Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA
WEBSITE	adicetbio.com
INDUSTRY	Biotechnology
EMPLOYEES	132

Adicet Bio, Inc. Frequently Asked Questions

What is the ticker symbol for Adicet Bio, Inc.? What does ACET stand for in stocks?

ACET is the stock ticker symbol of Adicet Bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adicet Bio, Inc. (ACET)?

As of Fri May 17 2024, market cap of Adicet Bio, Inc. is 131.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACET stock?

You can check ACET's fair value in chart for subscribers.

What is the fair value of ACET stock?

You can check ACET's fair value in chart for subscribers. The fair value of Adicet Bio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adicet Bio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ACET so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adicet Bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether ACET is over valued or under valued. Whether Adicet Bio, Inc. is cheap or expensive depends on the assumptions which impact Adicet Bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACET.

What is Adicet Bio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ACET's PE ratio (Price to Earnings) is -0.94 and Price to Sales (PS) ratio is 1.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACET PE ratio will change depending on the future growth rate expectations of investors.